Mycophenolate Mofetil Dose Adjustment in Pediatric Kidney Transplant Recipients

Author:

Labriffe Marc12ORCID,Micallef Ludovic1,Woillard Jean-Baptiste12,Monchaud Caroline12,Saint-Marcoux Franck12,Debord Jean12,Marquet Pierre12

Affiliation:

1. Pharmacology and Transplantation, INSERM U1248, Université de Limoges ; and

2. Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France.

Abstract

Background: The Immunosuppressant Bayesian Dose Adjustment web site aids clinicians and pharmacologists involved in the care of transplant recipients; it proposes dose adjustments based on the estimated area under the concentration–time curve (AUCs). Three concentrations (T20 min, T1 h, and T3 h) are sufficient to estimate mycophenolic acid (MPA) AUC0–12 h in pediatric kidney transplant recipients. This study investigates mycophenolate mofetil (MMF) doses and MPA AUC values in pediatric kidney transplant recipients, and target exposure attainment when the proposed doses were followed, through a large-scale analysis of the data set collated since the inception of the Immunosuppressant Bayesian Dose Adjustment web site. Methods: In this study, 4051 MMF dose adjustment requests, corresponding to 1051 patients aged 0–18 years, were retrospectively analyzed. AUC calculations were performed in the back office of the Immunosuppressant Bayesian Dose Adjustment using published Bayesian and population pharmacokinetic models. Results: The first AUC request was posted >12 months posttransplantation for 41% of patients. Overall, only 50% had the first MPA AUC0–12 h within the recommended 30–60 mg.h/L range. When the proposed dose was not followed, the proportion of patients with an AUC in the therapeutic range for MMF with cyclosporine or tacrolimus at the subsequent request was lower (40% and 45%, respectively) than when it was followed (58% and 60%, respectively): P = 0.08 and 0.006, respectively. Furthermore, 3 months posttransplantation, the dispersion of AUC values was often lower at the second visit when the proposed doses were followed, namely, P = 0.03, 0.003, and 0.07 in the 4 months–1 year, and beyond 1 year with <6-month or >6-month periods between both visits, respectively. Conclusions: Owing to extreme interindividual variability in MPA exposure, MMF dose adjustment is necessary; it is efficient at reducing such variability when based on MPA AUC.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3